• ViiV announces rolling submission of NDA for long-acting injectable PrEP

    4 days ago - By Healio

    ViiV Healthcare said Tuesday that it has initiated a rolling submission of a new drug application for long-acting injectable cabotegravir for HIV PrEP.
    The rolling submission will allow ViiV to submit portions of the application to the FDA as they are finished rather than waiting until all of the NDA is completed, the company noted.
    “With today's announcement, we're one step closer to being able to provide the first, long-acting, therapy to prevent HIV,” Kimberly Smith, MD, MPH, ViiV's head of research and development, said in a press release. “This is the
    Read more ...